Amylyx Pharmaceuticals, Inc. (AMLX) vs Denali Therapeutics Inc. (DNLI)
A side-by-side comparison of Amylyx Pharmaceuticals, Inc. and Denali Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMLX
Amylyx Pharmaceuticals, Inc.
$27.78HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
DNLI
Denali Therapeutics Inc.
$19.91HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AMLX vs DNLI
growth of $100 · dividends reinvested · last 5yAMLX +53.7% (+9.0%/yr)DNLI -54.7% (-14.7%/yr)AMLX compounded faster over this window
AMLX DNLI
AMLX vs DNLI: by the numbers
- •DNLI is the larger company ($3.16B vs $3.09B market cap).
- •Both run net losses; AMLX's is the smaller (0.00% vs -14191.20% net margin).
Metrics side by side
Valuation
| Metric | AMLX | DNLI |
|---|---|---|
| P/S ratio | N/A | 876.78 |
| P/B ratio | 12.91 | 3.78 |
Profitability
| Metric | AMLX | DNLI |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -14191.20% |
| ROE | -63.59% | -61.24% |
| ROIC | -66.60% | -50.82% |
Growth (annualized)
| Metric | AMLX | DNLI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 20.68% |
| Total return CAGR (5Y) | N/A | -16.91% |
Go deeper
Dig into the metrics
Amylyx Pharmaceuticals ROEDenali Therapeutics ROEAmylyx Pharmaceuticals operating marginDenali Therapeutics operating marginAmylyx Pharmaceuticals revenue growthDenali Therapeutics revenue growthAmylyx Pharmaceuticals free cash flowDenali Therapeutics free cash flow
Amylyx Pharmaceuticals & Denali Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.